CNB
VRTX icon

Camden National Bank’s Vertex Pharmaceuticals VRTX Stock Holding History

Camden National Bank’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.3M Sell
20,831
-76
-0.4% -$33.7K 1.35% 30
2026
Q1 		$9.34M Sell
20,907
-61
-0.3% -$28.4K 1.26% 35
2025
Q4 		$9.51M Buy
20,968
+76
+0.4% +$32.8K 1.31% 32
2025
Q3 		$8.18M Buy
20,892
+430
+2% +$180K 1.14% 40
2025
Q2 		$9.11M Sell
20,462
-204
-1% -$94K 1.31% 32
2025
Q1 		$10M Sell
20,666
-271
-1% -$126K 1.49% 28
2024
Q4 		$8.43M Sell
20,937
-187
-0.9% -$86.7K 1.26% 35
2024
Q3 		$9.82M Sell
21,124
-188
-0.9% -$90.3K 1.41% 33
2024
Q2 		$9.99M Buy
21,312
+2,742
+15% +$1.19M 1.54% 26
2024
Q1 		$7.76M Sell
18,570
-588
-3% -$249K 1.37% 38
2023
Q4 		$7.8M Sell
19,158
-500
-3% -$185K 1.45% 33
2023
Q3 		$6.84M Buy
19,658
+1,053
+6% +$368K 1.4% 34
2023
Q2 		$6.55M Sell
18,605
-272
-1% -$91.6K 1.28% 38
2023
Q1 		$5.95M Sell
18,877
-203
-1% -$60.9K 1.21% 40
2022
Q4 		$5.51M Sell
19,080
-348
-2% -$106K 1.15% 42
2022
Q3 		$5.63M Sell
19,428
-91
-0.5% -$26.2K 1.26% 41
2022
Q2 		$5.5M Buy
19,519
+204
+1% +$54.6K 1.14% 46
2022
Q1 		$5.04M Sell
19,315
-492
-2% -$117K 0.91% 51
2021
Q4 		$4.35M Buy
19,807
+281
+1% +$54.6K 0.76% 56
2021
Q3 		$3.54M Sell
19,526
-6,606
-25% -$1.29M 0.68% 60
2021
Q2 		$5.27M Sell
26,132
-1,232
-5% -$258K 0.99% 49
2021
Q1 		$5.88M Sell
27,364
-31
-0.1% -$6.81K 1.17% 41
2020
Q4 		$6.47M Buy
27,395
+11,561
+73% +$2.65M 1.35% 34
2020
Q3 		$4.31M Buy
15,834
+8,617
+119% +$2.38M 0.95% 47
2020
Q2 		$2.1M Buy
+7,217
New +$1.96M 0.52% 54

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Camden National Bank's VRTX Position: Q2 2026 in Review

Camden National Bank reduced its Vertex Pharmaceuticals (VRTX) stake by 0.36% in Q2 2026, selling an estimated $33.7K and leaving 20,831 shares worth $10.3M. The position accounts for 1.35% of the portfolio, ranked #30.

Camden National Bank first reported a position in VRTX in Q2 2020 and has held it in 25 quarters since. 734 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Camden National Bank held 20,831 shares of Vertex Pharmaceuticals worth $10.3M as of Q2 2026.
  • Camden National Bank sold 76 Vertex Pharmaceuticals shares in Q2 2026, an estimated $33.7K.
  • Vertex Pharmaceuticals made up 1.35% of Camden National Bank's portfolio in Q2 2026, its #30 holding.
  • Camden National Bank first reported a position in Vertex Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • 734 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Camden National Bank's 13F filing for Q2 2026, filed 31 Jul 2026.